Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease
(2012) In Acta Neurologica Scandinavica 126(6). p.29-33- Abstract
- Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, >= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD),... (More)
- Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, >= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD), baseline = 52.1 +/- 16.1, N = 27, month 0 (first visit; at least 3 months after permanent LCIG) = 43.1 +/- 16.7, N = 27, P = 0.003; month 12 = 42.5 +/- 22.6, n = 25, P = 0.017. PDQ-39 results also showed a tendency for improvement: PDQ-39 (mean +/- SD), baseline = 33.6 +/- 10.8, N = 27, month 0 = 27.1 +/- 11.8, N = 27, P = 0.001; 12 months = 28.8 +/- 12.8, n = 23, P = 0.126. Conclusions - LCIG provides functional improvement beginning at first visit that is sustained for 12 months. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3283349
- author
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- movement disorders, Parkinson's disease, quality of life, treatment
- in
- Acta Neurologica Scandinavica
- volume
- 126
- issue
- 6
- pages
- 29 - 33
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000310545400001
- scopus:84868190961
- pmid:22690905
- ISSN
- 1600-0404
- DOI
- 10.1111/j.1600-0404.2012.01689.x
- language
- English
- LU publication?
- yes
- id
- 69c25a97-7e13-4953-8712-24bbf00347e2 (old id 3283349)
- date added to LUP
- 2016-04-01 13:14:10
- date last changed
- 2022-05-15 03:23:40
@article{69c25a97-7e13-4953-8712-24bbf00347e2, abstract = {{Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, >= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD), baseline = 52.1 +/- 16.1, N = 27, month 0 (first visit; at least 3 months after permanent LCIG) = 43.1 +/- 16.7, N = 27, P = 0.003; month 12 = 42.5 +/- 22.6, n = 25, P = 0.017. PDQ-39 results also showed a tendency for improvement: PDQ-39 (mean +/- SD), baseline = 33.6 +/- 10.8, N = 27, month 0 = 27.1 +/- 11.8, N = 27, P = 0.001; 12 months = 28.8 +/- 12.8, n = 23, P = 0.126. Conclusions - LCIG provides functional improvement beginning at first visit that is sustained for 12 months.}}, author = {{Palhagen, S. E. and Dizdar, N. and Hauge, T. and Holmberg, B. and Jansson, R. and Linder, J. and Nyholm, D. and Sydow, O. and Wainwright, M. and Widner, Håkan and Johansson, A.}}, issn = {{1600-0404}}, keywords = {{movement disorders; Parkinson's disease; quality of life; treatment}}, language = {{eng}}, number = {{6}}, pages = {{29--33}}, publisher = {{Wiley-Blackwell}}, series = {{Acta Neurologica Scandinavica}}, title = {{Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease}}, url = {{http://dx.doi.org/10.1111/j.1600-0404.2012.01689.x}}, doi = {{10.1111/j.1600-0404.2012.01689.x}}, volume = {{126}}, year = {{2012}}, }